Lerdelimumab
From Wikipedia, the free encyclopedia
|
Lerdelimumab
|
|
|
|
|
| Source | Human |
| Target | CAT-152 |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Lerdelimumab is a human monoclonal antibody which it's used as an immunosuppressive drug.
[edit] External link
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Abatacept, Abetimus, Adalimumab, Afelimomab, Anakinra, Alefacept, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit), Aselizumab, Atlizumab, Atorolimumab, Azathioprine, Basiliximab, Belatacept, Belimumab, Bertilimumab, Cedelizumab, Ciclosporin, Citilimumab, Clenoliximab, Daclizumab, Difirolimus, Dofosirolimus, Dorlimomab aritox, Eculizumab, Efalizumab, Elsilimomab, Enlimomab, Enlimomab pegol, Erlizumab, Etanercept, Everolimus, Faralimomab, Fontolizumab, Galiximab, Gavilimomab, Gifosirolimus, Golimumab, Gomiliximab, Gusperimus, Infliximab, Inolimomab, Ipilimumab, Keliximab, Leflunomide, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Methotrexate, Morolimumab, Muromonab-CD3, Mycophenolic acid, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Pascolizumab, Pexelizumab, Pimecrolimus, Reslizumab, Rovelizumab, Ruplizumab, Safosirolimus, Siplizumab, Sirolimus, Tacrolimus, Talizumab, Telimomab aritox, Teneliximab, Thalidomide, Ticilimumab, Tilolizumab, Tocilizumab, Toralizumab, Torolimus, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
Adalimumab, Adecatumumab, Anetumumab, Atorolimumab, Belimumab, Bertilimumab, Betumumab, Cetforlimumab, Cetinlimumab, Cetlalimumab, Cetolimumab, Cynosumab, Denosumab, Duntumumab, Durimulumab, Durmulumab, Efungumab, Exbivirumab, Futumumab, Genosumab, Golimumab, Intumumab, Ipilimumab, Iratumumab, Lerdelimumab, Lexatumumab, Libivirumab, Mapatumumab, Metelimumab, Nebacumab, Ofatumumab, Panitumumab, Pritumumab, Raxibacumab, Regavirumab, Resatumumab, Restumumab, Rosutumumab, Sevirumab, Stamulumab, Synosumab, Ticilimumab, Tritumumab, Trixatumumab, Tuvirumab, Vexatumumab, Votumumab, Zalutumumab, Zanolimumab, Ziralimumab
